New Delhi : Bharat Biotech recently received approval from the drug regulator to conduct Phase-3 clinical trials of its nasal vaccine which is being considered as a potential booster dose…
Bharat Biotech has sought from the Drugs Controller General of India regular market approval for its COVID-19 vaccine ‘Covaxin’, which is currently only authorised for emergency use in the country,…
by Sudarshan JainThe pandemic continues to be a challenging humanitarian crisis globally with the Omicron variant sparking new fears. With the population facing a risk to their lives and livelihood,…
Two government vaccine makers, Haffkine Bio-Pharmaceutical Corporation and Bharat Immunologicals and Biologicals Corporation (BIBCOL), that signed up to produce Bharat Biotech’s Covaxin drug substance may not be in a position…
NEW DELHI: Myanmar, Bangladesh, Nepal and Iran have been the first recipients of resumed vaccine exports from India almost eight months after they were halted due to rising cases of…
Hyderabad, November 12, 2021: Bharat Biotech, a global leader in vaccine development and innovation, announced today that the safety and efficacy analysis data from Phase III clinical trials of COVAXIN®…
NEW DELHI: The World Health Organisation may have issued an emergency use listing for Covaxin but people fully vaccinated with the Bharat Biotech jab will have to wait for some…
Bharat Biotech’s Covaxin has taken less time than several other vaccines, Word Health Organsiation (WHO) said, clearing the air on criticism that the UN health agency took a longer time…
Hyderabad: World Health Organisation (WHO) Bharat Biotech’s Covaxin was granted Emergency Use Listing status for Covaxin on Wednesday evening after several rounds of discussions, following this announcement, Dr Krishna Ella,…
In a move that can boost travel across the countries, the Therapeutic Goods Administration (TGA) of Australia has granted recognition to Covaxin, indigenously developed by India’s Bharat Biotech International Limited.…
